World Health Assembly endorses new plan to increase global access to vaccines

World Health OrganizationMinisters of Health from 194 countries at the Sixty-fifth World Health Assembly endorsed a landmark Global Vaccine Action Plan (GVAP), a roadmap to prevent millions of deaths by 2020 through more equitable access to existing vaccines for people in all communities.

The GVAP was coordinated by the Decade of Vaccines Collaboration, a group of leading international vaccine experts, and represents the collective vision of hundreds of global health stakeholders to extend the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.

Currently, four out of every five children receive at least a basic set of vaccinations during infancy that allow them to lead healthy, productive lives. However, this means 20 percent of children still do not benefit from basic immunization.

This comprehensive plan involves four mutually reinforcing goals: strengthening routine immunization to meet vaccination coverage targets; accelerating control of vaccine-preventable diseases with polio eradication as the first milestone; introducing new and improved vaccines; and spurring research and development for the next generation of vaccines and technologies. The plan is expected to reduce global childhood mortality, surpassing the targets of the United Nations Millennium Development Goal 4.

"The Global Vaccine Action Plan focuses on the health needs of people at all stages of life," said Dr. Flavia Bustreo, Assistant Director-General for Family, Women's and Children's Health of the World Health Organization. "The plan promotes greater coordination and synergies between immunization and other child, adolescent and reproductive health interventions leading to healthier communities everywhere."

"While immunization already prevents millions of deaths and uncounted illness, we cannot rest until life-saving, cost-effective vaccine technology reaches people in every community and every country through this global plan," said Dr. Ciro de Quadros, Executive Vice President of the Sabin Vaccine Institute and co-chair of the Decade of Vaccines Collaboration's Steering Committee.

Following the approval by the World Health Assembly, the GVAP will be adapted for implementation at the regional and country level. Country involvement in this process reinforces a key tenet of the GVAP, which is to increase national ownership of immunization programs. The collaboration will also establish a monitoring and evaluation framework and finalize estimates for funding needs as well as potential cost savings.

"By supporting countries to strengthen their health systems and introduce powerful vaccines that prevent the biggest killers of children, we can have a dramatic impact on the lives of millions of people. We need to work together to make the vision of the Global Vaccine Action Plan a reality, and I am proud that GAVI will play its part in this," said Dr. Seth Berkley, CEO of the GAVI Alliance.

Innovation is a guiding principle of the GVAP beyond the vaccines themselves. The plan identifies priorities for improving program efficiency and increasing vaccine coverage. This includes the use of modern communication technologies for immunization programs; research to understand the cultural, economic and organizational determinants of immunization; and the development of diagnostic tools for conducting surveillance in low-income countries. The plan also focuses on building capacity and human resources in low- and middle-income countries to conduct research and development and operational research.

"We know vaccines work to save and improve lives," said Dr. Chris Elias, president of the global development program at the Bill & Melinda Gates Foundation. "We must urgently work to reach all children with the vaccines they need."

Lending further support to the Decade of Vaccines, world health ministers also endorsed a resolution declaring polio a global public health emergency. The eradication of polio is a critical step in protecting all children from vaccine-preventable diseases and is an important early milestone in the Decade of Vaccines.

A large and diverse group of stakeholders representing 290 organizations - including representatives and elected officials, health professionals, academics, manufacturers, global agencies, development partners, civil society, media and the private sector in more than 140 countries - contributed their expertise to the development of the GVAP in a year-long consultation process.

"It is unacceptable that children are still dying from diseases that are preventable with existing vaccines," said Dr. Abdul Majeed Siddiqi, Head of Mission for HealthNet TPO in Afghanistan and Pakistan and Chair of the GAVI Civil Society Steering Committee. "This is an actionable plan across the discovery, development and delivery of vaccines - now we must all do our part to make it happen."

Key representatives from the World Health Organization, UNICEF, the Bill & Melinda Gates Foundation, the GAVI Alliance, the U.S. National Institute of Allergy and Infectious Diseases and the African Leaders Malaria Alliance had central roles in the DoV Collaboration Leadership Council and working groups.

About the Decade of Vaccines Collaboration
The Decade of Vaccines Collaboration is an effort that has brought together diverse organizations, experts, scientists and governments to develop a Global Vaccine Action Plan that will stimulate the discovery, development, and delivery of lifesaving vaccines, to achieve the vision of a world in which all individuals and communities enjoy lives free from vaccine-preventable diseases. Its mission is to extend, by 2020 and beyond, the full benefits of immunization to all people, regardless of where they are born, who they are, or where they live.

About the World Health Organization
The World Health Organization, WHO, is the directing and coordinating authority on international health within the United Nations. With offices in over 147 countries, WHO is responsible for providing leadership on global health matters, shaping the health research agenda, setting norms and standards, articulating evidence-based policy options, providing technical support to countries and monitoring and assessing health trends. In addition to medical doctors, public health specialists, scientists and epidemiologists, WHO staff include people trained to manage administrative, financial, and information systems, as well as experts in the fields of health statistics, economics and emergency relief.

Most Popular Now

Pfizer receives positive FDA Advisory Committee vo…

Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration's (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that avail...

Engineered bacteria find tumors, then alert the au…

Combining discoveries in cancer immunology with sophisticated genetic engineering, Columbia University researchers have created a sort of "bacterial suicide squad" that ...

First nasal monoclonal antibody treatment for COVI…

A pilot trial by investigators from Brigham and Women's Hospital, a founding member of the Mass General Brigham healthcare system, tested the nasal administration of the ...

US FDA Advisory Committee votes to support effecti…

GSK plc (LSE/NYSE: GSK) announced that the US Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the avail...

"Semantic similarity" leads to novel dru…

The words that researchers use to describe their results can be harnessed to discover potential new treatments for Parkinson's disease, according to a new study published...

Tumour cells' response to chemotherapy is driven b…

Cancer cells have an innate randomness in their ability to respond to chemotherapy, which is another tool in their arsenal of resisting treatment, new research led by the...

Pfizer's ZAVZPRET™ (zavegepant) migraine nasal spr…

Pfizer Inc. (NYSE: PFE) today announced the U.S. Food and Drug Administration (FDA) has approved ZAVZPRET™ (zavegepant), the first and only calcitonin gene-related peptid...

Pfizer invests $43 billion to battle cancer

Pfizer Inc. (NYSE: PFE) and Seagen Inc. (Nasdaq: SGEN) today announced that they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a...

Nanosatellite shows the way to RNA medicine of the…

The RNA molecule is commonly recognized as messenger between DNA and protein, but it can also be folded into intricate molecular machines. An example of a naturally occur...

Gene and cell therapies to combat pancreatic cance…

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene an...

Scientists reveal a potential new approach to trea…

Scientists at the National Institutes of Health and Massachusetts General Hospital in Boston have uncovered a potential new approach against liver cancer that could lead ...

Normalizing tumor blood vessels may improve immuno…

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited e...